Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:51:20.431Z.
Calculation as of: 2026-10-06T17:51:20.431Z.
Quote observation: 2026-10-06T17:50:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2d28e84da0c930e75004ae600b803967d1975629f72cad3bf33ad83c9831f21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Eikon Therapeutics, Inc. Common Stock
Market Cap
$407.12M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$411.79M
Price/FCF Ratio
N/A
TTM Avg
4285.33
3Y Avg
985.66
5Y Avg
501.76
Market Cap
$410.17M
Price/FCF Ratio
N/A
TTM Avg
44.26
3Y Avg
44.26
5Y Avg
44.26
Market Cap
$411.20M
Price/FCF Ratio
N/A
TTM Avg
198.72
3Y Avg
198.72
5Y Avg
198.72
Market Cap
$402.33M
Price/FCF Ratio
N/A
TTM Avg
6.66
3Y Avg
6.66
5Y Avg
6.66
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $407.12M | N/A | N/A | N/A | N/A |
| Rezolute, Inc. (RZLT)vs › | $408.28M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $411.79M | N/A | 4285.33 | 985.66 | 501.76 |
| Prothena Corporation plc (PRTA)vs › | $410.17M | N/A | 44.26 | 44.26 | 44.26 |
| Shoulder Innovations, Inc. (SI)vs › | $407.30M | N/A | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $407.02M | N/A | N/A | N/A | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.20M | N/A | 198.72 | 198.72 | 198.72 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $402.33M | N/A | 6.66 | 6.66 | 6.66 |
| Carlsmed, Inc. (CARL)vs › | $403.70M | N/A | N/A | N/A | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
